{
  "id": 3791829,
  "title": "Dual MMP-9/12 Inhibition with AZD1236 Confers Neurovascular Protection and Reduces Post-Stroke Pain in Experimental Stroke Models.",
  "url": "https://urgent.news/2026/08/27/dual-mmp-9-12-inhibition-with-azd1236-confers-neurovascular",
  "topic": "science",
  "section": "Science",
  "published": "2026-08-27T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.08.23.746523v1?rss=1"
  },
  "original_language": "en",
  "account": "Dual inhibition of MMP-9 and MMP-12 with the drug AZD1236 offers significant neurovascular protection and alleviates post-stroke pain, according to experimental stroke models. This finding holds promise for the development of an adjunctive neuroprotective strategy to complement acute pharmacological treatment for ischaemic and haemorrhagic stroke, which currently has limited efficacy due to strict eligibility criteria and haemorrhagic risk associated with intravenous thrombolysis.",
  "summary": "Background: Stroke remains a leading cause of death and disability worldwide. Matrix metalloproteinases (MMPs), particularly MMP-9 and MMP-12, contribute to early blood-brain barrier (BBB) disruption, neuroinflammation, haemorrhagic transformation, and intracerebral haemorrhage (ICH). Intravenous thrombolysis is the only widely used pharmacological therapy for acute ischaemic stroke, but its…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}